Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter favorable biodistribution profile in non-human primates using a clinically validated editing strategy
You might also be interested in reading XRP Frenzy Builds: Over $1 Billion in Open Interest Signals Breakout Tension.